- Home
- MNTK vs OMER Comparison
MNTK vs OMER Comparison
Compare MNTK & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNTK
- OMER
- Stock Information
- Founded
- MNTK 1980
- OMER 1994
- Country
- MNTK United States
- OMER United States
- Employees
- MNTK N/A
- OMER N/A
- Industry
- MNTK Natural Gas Distribution
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- MNTK Utilities
- OMER Health Care
- Exchange
- MNTK Nasdaq
- OMER Nasdaq
- Market Cap
- MNTK 586.4M
- OMER 667.0M
- IPO Year
- MNTK 2021
- OMER 2009
- Fundamental
- Price
- MNTK $3.95
- OMER $7.88
- Analyst Decision
- MNTK Hold
- OMER Buy
- Analyst Count
- MNTK 2
- OMER 3
- Target Price
- MNTK $6.00
- OMER $9.00
- AVG Volume (30 Days)
- MNTK 170.7K
- OMER 1.0M
- Earning Date
- MNTK 11-12-2024
- OMER 11-13-2024
- Dividend Yield
- MNTK N/A
- OMER N/A
- EPS Growth
- MNTK 42.11
- OMER N/A
- EPS
- MNTK 0.16
- OMER N/A
- Revenue
- MNTK $194,849,000.00
- OMER N/A
- Revenue This Year
- MNTK $21.28
- OMER N/A
- Revenue Next Year
- MNTK $31.59
- OMER N/A
- P/E Ratio
- MNTK $24.39
- OMER N/A
- Revenue Growth
- MNTK 9.63
- OMER N/A
- 52 Week Low
- MNTK $3.38
- OMER $2.61
- 52 Week High
- MNTK $9.38
- OMER $12.65
- Technical
- Relative Strength Index (RSI)
- MNTK 37.86
- OMER 45.47
- Support Level
- MNTK $3.80
- OMER $7.33
- Resistance Level
- MNTK $4.35
- OMER $12.65
- Average True Range (ATR)
- MNTK 0.20
- OMER 1.06
- MACD
- MNTK 0.02
- OMER -0.63
- Stochastic Oscillator
- MNTK 22.86
- OMER 10.34
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a United States-based renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments: Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.